2020-12-21,"Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)"
2020-12-10,Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
2020-10-16,"Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020"
2020-10-02,Aptorum Group Announces Closing of $9.0 Million Public Offering
2020-09-29,Aptorum Group Announces Pricing of $9.0 Million Public Offering
2020-09-29,Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
2020-09-08,Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10
2020-09-08,Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
2020-09-02,Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
2020-09-01,"Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020"
2020-09-01,Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
2020-09-01,Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
2020-08-31,LD Micro: 360 Companies Set to Present this Week
2020-08-26,Aptorum Group Limited to Present at The LD 500 Virtual Conference
2020-08-26,Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference
2020-08-20,Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others
2020-08-05,LD Micro Announces Preliminary List of Presenters for the LD-500.
2020-07-24,Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM
2020-07-17,Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange
2020-07-03,Here's What Aptorum Group Limited's (NASDAQ:APM) Shareholder Ownership Structure Looks Like
2020-06-25,Analysts Recommend Catching These 2 Falling Knives
2020-06-15,Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman
2020-05-29,Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report
2020-04-29,Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
2020-04-29,Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update
2020-04-15,Aptorum Group Limited to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
2020-03-30,Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference
2020-03-30,Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
2020-03-30,Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform
2020-03-24,Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
2020-02-28,Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
2020-02-26,Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
2020-02-24,Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
2020-02-10,"Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020"
2020-02-10,Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
2020-01-03,Did You Manage To Avoid Aptorum Group's (NASDAQ:APM) 13% Share Price Drop?
2019-11-15,Aptorum Group Limited Announces Results of 2019 Annual General Meeting
2019-09-19,Aptorum Group Limited's (NASDAQ:APM) Single Biggest Risk For Investors
2019-09-09,Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
2019-09-09,"Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019"
2019-09-09,Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
2019-07-11,Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform
2019-07-08,Aptorum Groups subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN
2019-06-26,APM: Aptorum Focused on Development of Diseases with Significant Global Unmet Needs
2019-05-22,Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index
2019-05-15,Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States
2019-05-07,What Percentage Of Aptorum Group Limited (NASDAQ:APM) Shares Do Insiders Own?
2019-05-06,Aptorum Groups Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota
2019-04-30,UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)
2019-04-24,"USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations"
2019-04-24,"Aptorum Groups Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT"
2019-04-24,Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases
2019-04-24,"Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019"
2019-04-15,Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update
2019-04-01,Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer
2019-03-08,Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019
2019-03-04,Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019
2019-02-25,BRIEF-APM Automotive Posts Qtrly Net Profit Of 17.3 Million RGT
2018-12-07,Aptorum Group Limited Announces Pricing of Initial Public Offering
2018-02-28,BRIEF-APM Automotive Holdings Posts Qtrly Net Profit 13.1 Million RGT 
